Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, microvascular endothelial aging also disrupts the blood-brain barrier, which promotes neuroinflammation, exacerbating cognitive decline”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Montagne et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of claudins is associated with BBB breakdown in human neurodegenerative disorders (155, 569) and acute CNS diseases (692), as well as in animal models of these diseases (420), as discussed below.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reviewed, FDG-PET reflects mainly the transport activity of GLUT1 BBB transporter (420, 569).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides FDG-PET and verapamil-PET that have been used to test functions of BBB GLUT1 transporter and activity of ABCB1 (P-gp) efflux transporter in AD and PD (420, 569), respectively”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 6×
“…for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017).”
BackgroundInfluentialIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 13×
“…in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014).”
BackgroundInfluentialSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“, 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Rei- man et al., 2004; Sheline et al., 2010; Thambisetty et…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“3157JEM Vol. 214, No. 11 (PIC ALM) protein encoded by the PIC ALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ…”
Research works printed but not linked: 2
- Hachinski, 2016, Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation, Stroke., 47, e37
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Items 301–400 of 688
Understanding the Blood-Brain Barrier: From Physiology to Pathology
Garcia-Gallardo, A., & Campbell, M. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-89525-8_1 · Cited by 33
Ficiarà, E., Boschi, S., Ansari, S. A., D’Agata, F., Abollino, O., Caroppo, P., Fede, G. D., Indaco, A., Rainero, I., & Guiot, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.607858 · Cited by 31
Reddy, J. S., Allen, M., Ho, C. C. G., Oatman, S. R., İş, Ö., Quicksall, Z., Wang, X., Jin, J., Patel, T., Carnwath, T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01199-2 · Cited by 32
“We hypothesize this may occur as an event downstream of CAA, which induces reduced blood flow, or an upstream event leading to impairment in the neurovascular unit culminating in CAA [32].”
BackgroundZeng, M., Zhou, H., He, Y. T., Du, H., Yin, J.-J., Hou, Y., Zhu, J., Zhang, Y., Shao, C., Yang, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112048 · Cited by 30
Moon, Y., Jeon, H. J., Han, S., Noh, M., Kim, H.-J., Kwon, K. J., Moon, W., & Kim, S. H. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231180035 · Cited by 29
“2–6 Experimental studies indicate that dysfunction of BBB, which is implicated in amyloid protein efflux, can exacerbate beta-amyloid accumulation in the brain.”
BackgroundThe role of annexins in central nervous system development and disease
White, Z. B., Nair, S., & Bredel, M. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02443-7 · Cited by 28
“Modifications in blood-brain barrier permeability have been noted in patients diagnosed with Alzheimer’s disease [33].”
BackgroundMa, C., Ye, Y., Shi, X., Li, N., Mu, Z., Tan, T., Yin, H., Dai, J., Liu, Y., & Chen, H. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01787-7 · Cited by 29
“However, both its structure and function are frequently compromised [53].”
Luo, L., & Qiao, S. (2026) · European journal of medical research · doi:10.1186/s40001-026-03840-z · Cited by 28
“When the functions and structures of BBB are damaged, harmful blood components leak into the CNS, cells infiltrate, and abnormal transport and clearance of molecules occur, thereby leading to the occurrence of diseases [18].”
Genetic heterogeneity of Alzheimer’s disease in subjects with and without hypertension
Nazarian, A., Arbeev, K. G., Yashkin, A. P., & Kulminski, A. M. (2019) · GeroScience · doi:10.1007/s11357-019-00071-5 · Cited by 29
Astrocytes Modify Migration of PBMCs Induced by β-Amyloid in a Blood-Brain Barrier in vitro Model
Spampinato, S. F., Merlo, S., Fagone, E., Fruciano, M., Barbagallo, C., Kanda, T., Sano, Y., Purrello, M., Vancheri, C., Ragusa, M., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00337 · Cited by 28
Is oral lipid-based delivery for drug targeting to the brain feasible?
Brookes, A., Ji, L., Bradshaw, T. D., Stocks, M. J., Gray, D. A., Butler, J., & Gershkovich, P. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.004 · Cited by 29
Effect of β-amyloid on blood-brain barrier properties and function
Petrushanko, I. Y., Mitkevich, V. A., & Makarov, A. А. (2023) · Biophysical Reviews · doi:10.1007/s12551-023-01052-x · Cited by 29
Ko, E. C., Spitz, S., Pramotton, F. M., Barr, O. M., Xu, C., Pavlou, G., Zhang, S., Tsai, A., Maaser‐Hecker, A., Jorfi, M., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1251195 · Cited by 28
Sex-regulated gene dosage effect of PPARα on synaptic plasticity
Pierrot, N., Ris, L., Stancu, I., Doshina, A., Ribeiro, F., Tyteca, D., Baugé, E., Lalloyer, F., Malong, L., Schakman, O., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800262 · Cited by 29
“The ef fi ciency of the treatment of Tg mice could result from a breakdown of the blood – brain barrier in 5XFAD mice (Montagne et al, 2017).”
Hachinski, V., Einhäupl, K. M., Ganten, D., Alladi, S., Brayne, C., Stephan, B. C. M., Sweeney, M. D., Zloković, B. V., Iturria‐Medina, Y., Iadecola, C., et al. (2019) · International Journal of Stroke · doi:10.1177/1747493019871915 · Cited by 30
“In particular, vascular dysregulation appears to be one of the first signs in the temporal evolution of AD,(15) which gradually unfolds in the brain over one or two decades before the deposits of amyloid and tau start to become visible with molecular PET imaging.(98) For example, in an amyloid PET-magnetic resonnance…”
BackgroundLukiw, W. J., Li, W., Bond, T., & Zhao, Y. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00545 · Cited by 31
Alzheimer’s Disease: From Amyloid to Autoimmune Hypothesis
Arshavsky, Y. I. (2020) · The Neuroscientist · doi:10.1177/1073858420908189 · Cited by 30
In Vitro Evaluation of Pro- and Antioxidant Effects of Flavonoid Tricetin in Comparison to Myricetin
Chobot, V., Hadaček, F., Bachmann, G., Weckwerth, W., & Kubicová, L. (2020) · Molecules · doi:10.3390/molecules25245850 · Cited by 27
“In patients suffering from neurodegenerative diseases, the BBB is often damaged [47], and this may increase flavonoid penetration from blood to brain tissues.”
BackgroundGLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes
Bailey, J., Coucha, M. M., Bolduc, D. R., Burnett, F. N., Barrett, A. C., Ghaly, M., & Abdelsaid, M. A. (2022) · Diabetologia · doi:10.1007/s00125-022-05730-5 · Cited by 30
Pathogenesis of miR-155 on nonmodifiable and modifiable risk factors in Alzheimer’s disease
Liu, J.-J., Long, Y.-F., Xu, P., Guo, H.-D., & Cui, G.-H. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01264-z · Cited by 29
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 31
“multi-faceted approaches simultaneously targeting 1371 neuroinflammation [117, 155, 156], blood-brain bar1372 rier [157, 158], robust A processing and clearance 1373 by targeted immunotherapies [13], tau phospho1374 rylation [159], APOE4 [160–164], improving 1375 mitochondrial function [165–167], iPS cell-based 1376 d…”
BackgroundJović, M., Lončarević‐Vasiljković, N., Ivković, S., Dinić, J., Milanović, D., Zloković, B. V., & Kanazir, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216726 · Cited by 29
Rao, H. V., Bihaqi, S. W., Iannucci, J., Sen, A., & Grammas, P. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200658 · Cited by 29
“Reports from both human studies and animal models of AD document that cerebrovascular dysfunction precedes the development of cognitive impairment as well as AD pathology, and lowers the threshold for dementia for a given AD pathology burden [37].”
A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential
Greenfield, S. A., Cole, G. M., Coen, C. W., Frautschy, S. A., Singh, R. P., Mekkittikul, M., Garcia‐Ratés, S., Morrill, P. R., Hollings, O., Passmore, M., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12274 · Cited by 27
Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy
Yi, X., Jin, X., Hu, Y., Shen, Z., Zheng, X., Luo, D., Xu, T., Yan, J., & Huang, P. C. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00474 · Cited by 27
Yang, H., Wang, W., Jia, L., Qin, W., Hou, T., Wu, Q., Li, H., Tian, Y., & Jia, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191045 · Cited by 27
Fish oil protects the blood–brain barrier integrity in a mouse model of Alzheimer’s disease
Xie, Y., Yan, L., Zeng, H., Chen, W., Lu, J., Wan, J., Su, H., & Yao, X. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00314-0 · Cited by 26
Johnson, T. S., Xiang, S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2021) · Scientific Reports · doi:10.1038/s41598-020-79740-x · Cited by 38
Yue, Q., Zhou, X., Zhang, Z., & Hoi, M. P. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031878 · Cited by 26
“The disruption of BBB function and integrity has also been demonstrated in transgenic mice expressing mutations in human amyloid precursor protein (APP) and presenilin-1 (PSEN1) genes linked to autosomal dominant AD, manifested as leakage of molecules across the BBB, loss of TJ proteins, and dysregulated expressions o…”
BackgroundZhao, Y., Mao, X., Wang, H., Gan, L., Zhang, S., Gong, P., & Lin, X. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2103079 · Cited by 29
Effects of Hypertension on Alzheimer’s Disease and Related Disorders
Malone, J. E., Elkasaby, M., & Lerner, A. J. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01221-5 · Cited by 27
Reekes, T. H., Ledbetter, C. R., Alexander, J., Stokes, K. Y., Pardue, S., Bhuiyan, M. A. N., Patterson, J. C., Lofton, K. T., Kevil, C. G., & Disbrow, E. A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102633 · Cited by 26
Li, X., Zhang, Y., Chang, J., Zhang, C., Li, L., Dai, Y., Yang, H., & Wang, Y. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04716-9 · Cited by 27
“BBB breakdown and dysfunction lead to leakages of harmful blood components into the CNS in disease states, contributing to neurological deficits and aggravating disease [50].”
BackgroundAn Overview of the Blood-Brain Barrier
Barichello, T., Collodel, A., Hasbun, R., & Morales, R. (2018) · Neuromethods · doi:10.1007/978-1-4939-8946-1_1 · Cited by 31
Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice
Abdallah, I. M., Al-Shami, K. M., Yang, E., & Kaddoumi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031231 · Cited by 27
Delbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 28
Lin, W., Qin, Y., & Ren, Y. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.133113 · Cited by 25
Tsukita, K., Yano, T., Tamura, A., & Tsukita, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236012 · Cited by 25
Investigation of Potential Brain Microbiome in Alzheimer’s Disease: Implications of Study Bias
Westfall, S., Dinh, D. M., & Pasinetti, G. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191328 · Cited by 25
“One of the consequences of the inflammatory response to dysbiotic bacteria in AD is an opening of the epithelial barriers in the gut and the brain allowing increased infiltration of bacterial products and cells from the GI lumen into the brain [21, 22].”
Martin-Estebane, M., & Gomez-Nicola, D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00149 · Cited by 25
Impact of Wnt/β‐catenin signaling on ethanol‐induced changes in brain endothelial cell permeability
Laksitorini, M. D., Yathindranath, V., Xiong, W., Parkinson, F. E., Thliveris, J. A., & Miller, D. W. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15203 · Cited by 28
Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
Peña‐Bautista, C., Álvarez‐Sánchez, L., Ferrer, I., López‐Nogueroles, M., Martínez, A. J. C., Oger, C., Galano, J., Durand, T., Baquero, M., & Cháfer‐Pericás, C. (2021) · Antioxidants · doi:10.3390/antiox10071043 · Cited by 26
“It could be explained by the high permeability of the blood-brain barrier since early AD stages [17].”
BackgroundFibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
“Indeed, early BBB breakdown and dysfunction occur in AD and dementia patients before neurodegeneration and brain atrophy (18–20).”
BackgroundQin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 27
“As an example, in mice, it was shown that a combination of ApoE deficiency and high-fat diet, but not these conditions on their own, leads to BBB disruption and neuropathology [27], as would be useful in research on comorbidities in AD.”
BackgroundInfluentialThe Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 25
Luckey, A. M., Robertson, I. H., LAWLOR, B. A., Mohan, A., & Vanneste, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210404 · Cited by 24
Zhang, F., & Wang, D. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1191445 · Cited by 29
“Under pathological conditions, a variety of inflammatory stimuli, such as cytokines, LPS, amyloid β (Aβ) and tau fragments may initiate an inflammatory response in endothelial cells of the blood brain barrier (BBB), which activates a variety of signaling pathways and consequently results in neurovascular abnormalities…”
BackgroundThe role of macrophage plasticity in neurodegenerative diseases
Ma, H., Zhu, M., Chen, M., Li, X., & Feng, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00624-7 · Cited by 25
Efficient SSA ‐mediated precise genome editing using CRISPR /Cas9
Li, X., Bai, Y., Cheng, X., Kalds, P., Sun, B., Wu, Y., Lv, H., Xu, K., & Zhang, Z. (2018) · FEBS Journal · doi:10.1111/febs.14626 · Cited by 26
Blood Pressure Control and Protection of the Aging Brain
Wahidi, N., & Lerner, A. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00747-y · Cited by 26
Ayoub, S., Arabi, M., Al-Najjar, Y. A., Laswi, I., Outeiro, T. F., & Châari, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05051-9 · Cited by 27
“These modified Aβ species resist proteasomal degradation, contributing to plaque accumulation [42].”
Clasen, M. M., Riley, A. L., & Davidson, T. L. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200206091447 · Cited by 23
Sharma, A., Muresanu, D. F., Nozari, A., Lafuente, J. V., Sahib, S., Tian, Z. R., Buzoianu, A. D., Patnaik, R., Wiklund, L., & Sharma, H. S. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.09.010 · Cited by 24
Angom, R. S., Kulkarni, T., Wang, E., Dutta, S. K., Bhattacharya, S., Das, P., & Mukhopadhyay, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.903047 · Cited by 24
Schreiner, T. G., Creangă-Murariu, I., Tamba, B.-I., Lucanu, N., & Popescu, B. O. (2022) · Biomolecules · doi:10.3390/biom12081136 · Cited by 24
“AD is a relevant example of a frequent neurological disorder associated with important BBB damage [117].”
BackgroundDenkinger, M. N., Baker, S. L., Inglis, B. A., Kobayashi, S., Juarez, A., Mason, S., & Jagust, W. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299764 · Cited by 23
Liu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
“In the BBB pathway, the capillary lengths in mouse and human brains are approximately 0.6 km and 650 km, respectively, which account for more than 85% of the total length of cerebral blood vessels, providing a large surface area for substance exchange between the blood and the brain [24, 51].”
BackgroundInfluentialPage, S., Patel, R., Raut, S., & Al-Ahmad, A. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.009 · Cited by 25
Chaubey, K., Vázquez‐Rosa, E., Tripathi, S. J., Shin, M., Yu, Y., Dhar, M., Chakraborty, S., Yamakawa, M., Wang, X., Sridharan, P. S., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102535 · Cited by 32
Boltze, J., Aronowski, J. A., Badaut, J., Buckwalter, M. S., Caleo, M., Chopp, M., Dave, K. R., Didwischus, N., Dijkhuizen, R. M., Doeppner, T. R., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.623751 · Cited by 24
“The epigenetic modification hydroxymethylation that converts 5-methylcytosine to 5-hydroxymethylcytosine induced after stroke is neuroprotective in both sexes (Morris-Blanco et al., 2019).”
BackgroundSelf-citationYoshikawa, M., Aizawa, S., Oppenheim, R. W., & Milligan, C. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114084 · Cited by 23
Is Alzheimer’s disease a polymicrobial host microbiome dysbiosis?
Singhrao, S. K., & Harding, A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1729741 · Cited by 22
Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
Hodges, A. K., Piers, T. M., Collier, D., Cousins, O., & Pocock, J. M. (2021) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.60 · Cited by 21
“infections([8]) and in advanced stages of diseases such as AD([9-11]).”
Natale, G., Clouston, S., & Smith, D. M. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab282 · Cited by 22
“the blood-brain barrier (BBB) plays in AD pathogenesis (9).”
BackgroundLinton, A. E., Weekman, E. M., & Wilcock, D. M. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100030 · Cited by 22
Roles of Siglecs in neurodegenerative diseases
Siew, J. J., Chern, Y., Khoo, K., & Angata, T. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101141 · Cited by 23
Hnilicová, P., Kantorová, E., Šutovský, S., Grofik, M., Zeleňák, K., Kurča, E., Žilka, N., Parvanovova, P., & Kolísek, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043325 · Cited by 23
“BBB breakdown induces neurodegenerative pathophysiological processes such as chronic inflammation, oxidative stress, deterioration of mitochondrial homeostasis, and related damage to the energy metabolism of neurons, sentencing them to gradual death [141,143].”
BackgroundThe blood–brain barrier as a treatment target for neurodegenerative disorders
Rust, R., Sagare, A. P., Zhang, M., Zloković, B. V., & Kisler, K. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2480654 · Cited by 27
“In fact, it has been suggested that vascular dysfunction and BBB dysfunction may be central events that initiate and/or contribute to neuronal and synaptic dysfunction, neurodegeneration, cognitive dysfunction, and pathology in AD and related disorders [24,25].”
Disease-directed engineering for physiology-driven treatment interventions in neurological disorders
Wood, T. R., & Nance, E. A. (2019) · APL Bioengineering · doi:10.1063/1.5117299 · Cited by 21
Chu, W. H., Sun, X., Zhu, X., Zhao, Y. C., Zhang, J., Kong, Q. Q., & Zhou, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111698 · Cited by 21
Gaire, B. P., Koronyo, Y., Vit, J., Hutton, A., Subedi, L., Fuchs, D.-T. S., Swerdlow, N., Rentsendorj, A., Shahin, S., Martinon, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68580-4 · Cited by 20
Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
Hane, F. T., Li, T., Plata, J. A., Hassan, A. A., Granberg, K., & Albert, M. S. (2018) · Diagnostics · doi:10.3390/diagnostics8020041 · Cited by 21
“Additionally, AD is known to breakdown the blood brain barrier (BBB) [90].”
Vascular endothelial cells: a fundamental approach for brain waste clearance
Wei, H., Jiang, H., Zhou, Y., Xiao, X., Zhou, C., & Ji, X. (2022) · Brain · doi:10.1093/brain/awac495 · Cited by 23
Zhang, X., Zhang, Y., Zhang, L., & Qin, C. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12324 · Cited by 20
“induced by Aβ25- 35, (3) increased the expression of TJPs, including ZO1 and claudin5,”
BackgroundThe Role of Astrocytes and Blood–Brain Barrier Disruption in Alzheimer’s Disease
Cruz, J. V. R., Batista, C., Diniz, L. P., & Mendes, F. A. (2023) · Neuroglia · doi:10.3390/neuroglia4030015 · Cited by 20
“Under disease conditions, BBB breakdown and dysfunction leads to NVU dysregulation and defective signaling, resulting in cellular infiltration into the CNS, along with the aberrant transport and clearance of molecules, contributing to neurological deficits [7].”
BackgroundCellular junction dynamics and Alzheimer’s disease: a comprehensive review
Asghari, K., Niknam, Z., Mohammadpour-Asl, S., & Chodari, L. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09242-w · Cited by 20
“Dysfunction of AJs in the BBB can lead to increased permeability and inflammation [ 76], contributing to the pathogenesis of neurodegenerative diseases such as multiple sclerosis and AD [79, 80].”
Hosseininasab, S. S. M., Ebrahimi, R., Yaghoobpoor, S., Kazemi, K., Khakpour, Y., Hajibeygi, R., Mohamadkhani, A., Fathi, M., Vakili, K. G., Tavasol, A., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1513095 · Cited by 21
Joseph, C. R. (2020) · Biomedicines · doi:10.3390/biomedicines8070228 · Cited by 20
“The associated dysfunction in metabolic substrate transport, leak in of blood born toxins, and impaired blood flow regulation may be the initial “hit” in the complex development of AD and possibly other neurodegenerative diseases [21].”
BackgroundInfluentialVascular Effects on Cerebrovascular Permeability and Neurodegeneration
Sulimai, N., Brown, J. D., & Lominadze, D. G. (2023) · Biomolecules · doi:10.3390/biom13040648 · Cited by 19
Cellular mechanisms of fibrin (ogen): insight from neurodegenerative diseases
Wen, T., & Zhang, Z. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1197094 · Cited by 21
Microphysiological Systems for Neurodegenerative Diseases in Central Nervous System
Bae, M., Yi, H., Jang, J., & Cho, D. (2020) · Micromachines · doi:10.3390/mi11090855 · Cited by 19
Verheggen, I. C. M., Freeze, W. M., de Jong, J. J. A., Jansen, J. F. A., Postma, A. A., van Boxtel, M. P. J., Verhey, F. R. J., & Backes, W. H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.04.025 · Cited by 19
“Over the last years, there has been great interest in studies investigating the association between blood-brain barrier (BBB) disruption, aging and neurodegeneration (Erdő et al., 2017; van de Haar et al., 2016; Montagne et al., 2017; Zlokovic, 2008).”
Liu, Q., Liu, X., Zhao, D., Ruan, X., Su, R. J., Shang, X., Wang, D., Yang, C., & Xue, Y. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00531-y · Cited by 20
“The transition between the dysfunction of ECs and the deposition of Aβ in neurons promotes the development of AD [7].”
BackgroundThe ATX–LPA Axis Regulates Vascular Permeability during Cerebral Ischemic-Reperfusion
Bhattarai, S., Sharma, S., Subedi, U., Ara, H., Shum, A., Milena, M., Bhuiyan, M. S., Kidambi, S., Sun, H., Miriyala, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084138 · Cited by 19
“The BBB keeps neurotoxic plasma-derived components, cells, and pathogens away from the brain [2].”
BackgroundThe Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Quelhas, P., Baltazar, G., & Cairrão, E. (2019) · Current Neurovascular Research · doi:10.2174/1567202616666191026122642 · Cited by 20
Bei, J., Miranda-Morales, E. G., Gan, Q., Qiu, Y., Husseinzadeh, S., Liew, J. Y., Chang, Q., Krishnan, B., Gaitas, A., Yuan, S., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230347 · Cited by 22
“BBB dysfunction is primarily caused by reduced or disorganized TJ/AJ proteins or enhanced transendothelial bulk flow of specific molecules by transcytosis[1, 2, 35].”
Paradela, R. S., Justo, A. F. O., Paes, V. R., Leite, R. E. P., Pasqualucci, C. A., Grinberg, L. T., Naslavsky, M. S., Zatz, M., Nitríni, R., Filho, W. J., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01681-z · Cited by 19
“In addition, experimental studies with animals suggest that β-amyloid and tau are associated with blood vessel dysfunction and blood–brain-barrier (BBB) damage, which could facilitate the entrance of neurotoxic plasma-derived components into the brain [39].”
BackgroundReview of theories into the pathogenesis of normal pressure hydrocephalus
Mani, R., Basem, J. I., Yang, L. K., Fiore, S., Djurić, P. M., & Egnor, M. R. (2024) · BMJ Neurology Open · doi:10.1136/bmjno-2024-000804 · Cited by 19
“AD and NPH both share similar pathophysiology through impairments in glymphatic clearance.”
The Neurovascular Unit in Dementia: An Opinion on Current Research and Future Directions
Beishon, L., & Panerai, R. B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.721937 · Cited by 22
Liu, S., Song, G., Li, F., Li, R., Chen, X., Guo, Y., Zhou, F., Wang, Q., Yang, L., & Zhou, B. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.127386 · Cited by 18
Ye, X., Chen, J., Pan, J., Wu, Q., Wang, Y., Lu, M., Zhang, C., Zhang, Z., Ma, M., Zhu, J., et al. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2136525 · Cited by 18
“Neuroimaging and immunostaining of human AD brain specimens showed loss of cerebrovascular integrity, impaired BBB structure, abnormal peripheral deposits, and macrophage infiltration (Hultman et al. 2013; Montagne et al. 2017; Sweeney et al. 2018; van de Haar et al. 2016).”
BackgroundTreating Pain in Patients With Dementia and the Possible Concomitant Relief of Symptoms of Agitation
Pergolizzi, J. V., Raffa, R. B., Paladini, A., Varrassi, G., & LeQuang, J. A. (2019) · Pain Management · doi:10.2217/pmt-2019-0024 · Cited by 18
Models and mechanisms of post-stroke dementia and cognitive impairment
Khan, R., Devlin, P., Urayama, A., & Ritzel, R. M. (2025) · Frontiers in Stroke · doi:10.3389/fstro.2025.1563924 · Cited by 18
“…rates of transcytosis, and extremely limited fenestrations, which protects brain cells from direct exposure to circulating factors (Zlokovic, 2008; Montagne et al., 2017; Sweeney et al., 2018; Erickson and Banks, 2013; Erickson et al., 2012; Hashimoto et al., 2023; Kadry et al., 2020; Daneman and…”
Exercise and the blood–brain barrier: Mechanistic insights and therapeutic implications
Sun, Z.-X., Xie, F., Zhao, Y. F., Wang, X., Sun, Z.-W., Qian, L., & Feng, H. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107166 · Cited by 18
Evidence of emerging BBB changes in mid‐age apolipoprotein E epsilon‐4 carriers
Alruwais, N. M., Rusted, J. M., Tabet, N., & Dowell, N. G. (2022) · Brain and Behavior · doi:10.1002/brb3.2806 · Cited by 17
“Furthermore, studies have shown that the APOEε4 genotype is a risk factor for developing vascular diseasewhich could promote LOAD via blood–brain barrier (BBB) dysfunction (Montagne et al., 2015, 2016, 2017, 2018, 2020, 2021; Nelson et al., 2016).”
BackgroundModelling Alzheimer's disease using human brain organoids: current progress and challenges
Yanakiev, M., Soper, O., Berg, D. A., & Kang, E. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.40 · Cited by 18
Castillo-González, J., Ruiz, J. L., Serrano-Martínez, I., Forte‐Lago, I., Ubago-Rodríguez, A., Caro, M., Pérez‐Gómez, J. M., Benítez-Troncoso, A., Andrés‐León, E., Sánchez‐Navarro, M., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02908-5 · Cited by 17
“Given the scarce number of therapeutic agents available to restore BBB function in neurodegeneration [79, 80], the use of multi-factorial agents that target at the same time components of the TJ complex, modulate endothelial permeability at different grades, and control immune dysregulation, looks…”
BackgroundCerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models
Fang, X., Fan, F., & Roman, R. J. (2024) · Journal of Experimental Neurology · doi:10.33696/neurol.5.087 · Cited by 20
“A recent comprehensive review suggests that the elevation in BBB leakage in the various rodent models of AD is linked to a loss of endothelial cell tight junctions, capillary endothelial cell injury, loss of pericytes and activation of glial cells and perivascular macrophages [221].”
BackgroundSingh, P. K., Badimon, A., Chen, Z., Strickland, S., & Norris, E. H. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12504 · Cited by 20
Targeting Pdzrn3 maintains adult blood-brain barrier and central nervous system homeostasis
Gueniot, F., Rubin, S., Bougaran, P., Abélanet, A., Morel, J., Bontempi, B., Proust, C., Dufourcq, P., Couffinhal, T., & Duplàa, C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211048981 · Cited by 17
“Interestingly, it was shown that mechanisms of autoregulation of BBB permeability via a transient decrease of both Claudin5 and Occludin may enhance diffusion of Ab (1-40) monomers across BBB 60 underlying the functional role of BBB in amyloid fragment clearance.”
Background
Metadata
- Authors
- Montagne, A., Zhao, Z., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-10-23
- Volume
- 214
- Issue
- 11
- Pages
- 3151-3169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5679168
- OpenAlex
- W2766949297
- Cited by
- 672
- References
- 200
- Citations by year
- 2026: 54 · 2025: 56 · 2024: 93 · 2023: 82 · 2022: 82 · 2021: 90 · 2020: 91 · 2019: 76 · 2018: 46 · 2017: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01AG023084, R01NS090904, R01NS034467, R01AG039452, 5P01AG052350)
- Cure for Alzheimer’s Fund
- Alzheimer’s Association
- Fondation Leducq (16 CVD 05)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier dysfunction, blood-brain barrier disruption, neurodegeneration, amyloid precursor protein, presenilin 1, tau mutations, apolipoprotein E, transgenic mouse model, BBB repair
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Amyloid beta-Protein Precursor, tau Proteins, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.